Assessing Gender Differences for Non-Predictable Breakthrough Cancer Pain Phenomenon: A Secondary Analysis from IOPS-MS Study
Sabrina Bimonte,Piergiacomo Di Gennaro,Anna Crispo,Sergio Coluccia,Assunta Luongo,Alfonso Amore,Egidio Celentano,Francesco Del Prato,Daniela Schiavo,Davide Nocerino,Marco Cascella,Arturo Cuomo
DOI: https://doi.org/10.2147/jpr.s445222
IF: 2.8319
2024-09-05
Journal of Pain Research
Abstract:Sabrina Bimonte, 1, &ast Piergiacomo Di Gennaro, 2, &ast Anna Crispo, 2 Sergio Coluccia, 2 Assunta Luongo, 2 Alfonso Amore, 3, 4 Egidio Celentano, 2 Francesco Del Prato, 1 Daniela Schiavo, 1 Davide Nocerino, 1 Marco Cascella, 5 Arturo Cuomo 1 1 Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy; 2 Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy; 3 Melanoma and Sarcoma Surgery Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy; 4 PhD School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Rome, Italy; 5 Department of Medicine, University of Salerno, Salerno, Italy &astThese authors contributed equally to this work Correspondence: Anna Crispo, Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Via Mariano Semmola 53, Naples, Italy, Tel +39 081 17770298, Email Purpose: Breakthrough cancer pain (BTcP) is a temporary exacerbation of pain that "breaks through" a phase of adequate pain control by an opioid-based therapy. The non-predictable BTcP (NP-BTcP) subtype occurs in the absence of any specific activity. Evidence showed that gender differences exist in pain response sensitivity and clinical pain risk. This analysis aimed to signify the gender differences for the NP-BTcP phenomenon. Patients and Methods: This is a secondary analysis of the Italian Oncologic Pain multiSetting-Multicentric Survey (IOPS-MS), the largest study on BTcP. The subset of NP-BTcP cases for non-gender-specific cancer was considered. Univariable and multivariate analyses were conducted to identify gender differences for the NP-BTcP profile about its intensity, number of episodes per day, and type. A metastatic status-stratified analysis was performed to compare gender with the main clinical variables among the population with NP-BTcP. Results: Males exhibited a higher occurrence of BTcP in the thorax region compared to females (15% vs 11%, respectively, p = 0.03). Males also had a higher onset of BTcP, a higher BTcP therapy dosage (33% vs 28%, p = 0.04, mean: 201 vs 186, p = 0.02) and a lower Karnofsky score (mean: 46.9 vs 49.2, p = 0.03) compared to females. Similar gender differences were found for metastatic patients in the BTcP site (14% vs 8.5%, respectively; p = 0.01), peak onset (33% vs 27%, p = 0.02), BTcP therapy dosage (199 vs 185, p=0.04), and Karnofsky score (mean 47.5 vs 50.4, p = 0.009). Phenotype 2 was more characterized by non-metastatic males (41% vs 23%, p = 0.020) while non-metastatic females presence was predominant among others. Conclusion: In this study, gender differences according to site, onset and dosage of BTcP were found. The phenotype characterization of BTcP needs to be further investigated for a possible useful function in the management of cancer-related pain in non-metastatic patients. Keywords: non-predictable breakthrough cancer pain, gender cancer pain, cluster analysis Cancer pain is a debilitating condition and has severe effects on patients' quality of life. 1,2 The breakthrough cancer pain (BTcP) phenomenon represents a clinical peculiarity of cancer, which is characterized by a temporary exacerbation of pain that "breaks through" a phase of adequate control by an opioid-based therapy. 3,4 This symptom can affect up to 70% of patients with cancer. 5,6 Notably, two types of BTcP have been recognized: predictable BTcP (P-BTcP) and non-predictable BTcP (NP-BTcP) that have different features according to pathophysiology, clinical and therapeutic involvements. 7,8 The P-BTcP is subdivided into three subgroups: the volitional BTcP (caused by a voluntary act), the non-volitional subtype (provoked by an involuntary act), and the procedural pain. The NP-BTcP occurs in the absence of any specific activity, which is also called idiopathic or spontaneous BTcP. 9,10 Shreds of evidence demonstrate that men and women differ in their responses to pain. Specifically, women showed both greater sensitivity to pain and higher clinical risk than men; as reported by Bartley et al, many biopsychosocial mechanisms contribute to these sex differences in pain, including gender roles, sex hormones, endogenous opioid function and genetic factors. 11 In this paper, we described the results of a secondary analysis based on the Italian Oncologic Pain multiSetting-Multicentric Survey (IOPS-MS) focusing on gender differences regarding non-gender-specific cancer (No -Abstract Truncated-
clinical neurology